Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO1998052562) PHARMACEUTICAL COMPOSITION CONTAINING USCHARIDIN OR ITS ANALOGUES
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/1998/052562 International Application No.: PCT/GB1998/001522
Publication Date: 26.11.1998 International Filing Date: 26.05.1998
Chapter 2 Demand Filed: 23.12.1998
IPC:
A61K 31/365 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
335
having oxygen as the only ring hetero atom, e.g. fungichromin
365
Lactones
Applicants:
PHYTO CORPORATION LIMITED [GB/GB]; Prince Consort House Albert Embankment London SE1, GB (AllExceptUS)
STIMSON, William, Howard [GB/GB]; GB (UsOnly)
GRAY, Alexander, Irvine [GB/GB]; GB (UsOnly)
Inventors:
STIMSON, William, Howard; GB
GRAY, Alexander, Irvine; GB
Agent:
MURGITROYD & COMPANY; 373 Scotland Street Glasgow G5 8QA, GB
Priority Data:
9710698.324.05.1997GB
Title (EN) PHARMACEUTICAL COMPOSITION CONTAINING USCHARIDIN OR ITS ANALOGUES
(FR) COMPOSITION PHARMACEUTIQUE CONTENANT DE L'USCHARIDINE OU SES ANALOGUES
Abstract:
(EN) The invention provides compositions comprising uscharin and the use of uscharin to combat cell proliferation for example in the treatment of cancer. Administration of uscharin may kill or reduce the growth rate of cancer cells and may also be of application in other medical conditions presenting symptoms of excessive or uncontrolled cell proliferation. The composition may be administered by any convenient route and formulated accordingly. The composition may be administered locally or generally and may be suitably dissolved and/or suspended in a pharmaceutically acceptable liquid carrier medium.
(FR) L'invention concerne des compositions comprenant de l'uscharine et l'utilisation d'uscharine pour combattre la prolifération de cellules, par exemple dans le traitement du cancer. L'administration d'uscharine peut permettre de tuer les cellules cancéreuses ou de réduire leur vitesse de croissance, et peut également servir dans d'autres états pathologiques présentant des symptômes de prolifération cellulaire excessive ou non régulée. La composition peut être administrée par tout moyen approprié et peut être formulée en conséquence. La composition peut être administrée localement ou généralement et peut être dissoute et/ou mise en suspension de manière appropriée dans un excipient liquide acceptable du point de vue pharmaceutique.
Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW
African Regional Intellectual Property Organization (ARIPO) (GH, GM, KE, LS, MW, SD, SZ, UG, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)
Also published as:
EP0983063US6342490JP2001527569 CA2291132DE000069803059NZ501421
AU1998075431